Positions

Overview

  • Dr. Falkson joined the Hematology/Oncology Faculty at UAB as a Professor of Medicine and Senior Scientist, Comprehensive Cancer Center in 2001. She is an alumnus of the MD Anderson Cancer Center.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2018 Tucatinib combined with ado-Trastuzumab emtansine in advanced ERBB2/HER2-positive metastatic breast cancer: A Phase 1b Clinical TrialJAMA Oncology.  4:1214-1220. 2018
    2018 Everolimus Plus Endocrine Therapy for Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Clinical Trial.JAMA Oncology.  4:977-984. 2018
    2017 A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).Breast Cancer Research and Treatment.  165:375-382. 2017
    2016 Accuracy of Medicare Claim-based Algorithm to Detect Breast, Prostate, or Lung Cancer Bone Metastases.Medical Care2016
    2015 Phase II Study of Lapatinib in Combination With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Clinical Outcomes and Predictive Value of Early [18F]Fluorodeoxyglucose Positron Emission Tomography Imaging (TBCRC 003).Journal of Clinical Oncology.  33:2623-2631. 2015
    2013 Mortality following bone metastasis and skeletal-related events among patients 65 years and above with lung cancer: A population-based analysis of U.S. Medicare beneficiaries, 1999-2006.Lung India.  30:20-26. 2013
    2012 Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial.Lancet Oncology.  13:734-742. 2012
    2012 Analysis of Fcγ receptor IIIa and IIa polymorphisms: lack of correlation with outcome in trastuzumab-treated breast cancer patients.Clinical Cancer Research.  18:3478-3486. 2012
    2012 Mortality following bone metastasis and skeletal-related events among women with breast cancer: a population-based analysis of U.S. Medicare beneficiaries, 1999-2006.Breast Cancer Research and Treatment.  131:231-238. 2012
    2011 Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.Lancet.  378:771-784. 2011
    2011 Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006.Prostate Cancer and Prostatic Diseases.  14:177-183. 2011
    2011 Phase II Trial of Docetaxel and Carboplatin in Patients With Advanced Squamous Carcinoma of the Esophagus (E2298): A Trial of the Eastern Cooperative Oncology Group.Gastrointestinal cancer research : GCR.  4:9-14. 2011
    2010 Phase II study of interleukin-4 in indolent B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E5Y92).Journal of Immunotherapy.  33:1006-1009. 2010
    2010 Pilot trial of preoperative (neoadjuvant) letrozole in combination with bevacizumab in postmenopausal women with newly diagnosed estrogen receptor- or progesterone receptor-positive breast cancer.Clinical Breast Cancer.  10:275-280. 2010
    2010 Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast.JNCI Monographs.  2010:162-177. 2010
    2008 Receipt of standard breast cancer treatment by African American and White women.International Journal of Medical Sciences.  5:181-188. 2008
    2007 Tumor exosomes inhibit differentiation of bone marrow dendritic cells.Journal of Immunology.  178:6867-6875. 2007
    2005 Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.Lancet.  366:2087-2106. 2005
    2005 S0307. Phase III trial of bisphosphonates as adjuvant therapy for primary breast cancer.Clinical Advances in Hematology and Oncology.  3:852-854. 2005
    2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.Lancet.  365:1687-1717. 2005
    2005 Vinorelbine and cisplatin in advanced squamous cell carcinoma of the cervix: the South African experience.Anticancer Research.  25:2489-2492. 2005
    2005 A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma.Leukemia & Lymphoma.  46:197-206. 2005
    2004 Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial.Annals of Oncology.  15:743-750. 2004
    2004 A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96.Gynecologic Oncology.  92:957-964. 2004
    2003 Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial.Journal of Clinical Oncology.  21:968-975. 2003
    2003 Phase II Study of Ifosfamide+Doxorubicin in Patients With Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group.Sarcoma.  7:9-11. 2003
    2001 Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93).Cancer Journal.  7:155-164. 2001
    2000 Absence of commonly recurring BRCA1 mutations in black South African women with breast cancer.South African Medical Journal.  90:788. 2000
    2000 21-day oral etoposide for metastatic breast cancer: a phase II study and review of the literature.American Journal of Clinical Oncology.  23:258-262. 2000
    2000 Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196.Journal of Clinical Oncology.  18:2369-2377. 2000
    2000 Prognostic value of histologic grade and proliferative activity in axillary node-positive breast cancer: results from the Eastern Cooperative Oncology Group Companion Study, EST 4189.Journal of Clinical Oncology.  18:2059-2069. 2000
    2000 Development of three African language translations of the FACT-G.Quality of Life Research.  9:139-149. 2000
    2000 Treatment of squamous cell esophageal cancer with topotecan: an Eastern Cooperative Oncology Group Study (E2293).American Journal of Clinical Oncology.  23:45-46. 2000
    1999 Phase II trial of doxorubicin and paclitaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: an Eastern Cooperative Oncology Group Study.Journal of Clinical Oncology.  17:3828-3834. 1999
    1999 A phase II evaluation of clofazimine plus doxorubicin in advanced, unresectable primary hepatocellular carcinoma.Oncology.  57:232-235. 1999
    1999 Carcinoma of unknown primary site--leave it unknown.South African Medical Journal.  89:844-845. 1999
    1998 A randomized study of radiotherapy alone versus radiotherapy plus 5-fluorouracil and platinum in patients with inoperable, locally advanced squamous cancer of the esophagus.American Journal of Clinical Oncology.  21:462-465. 1998
    1998 Extended survival in 80 patients with operable, locoregionally recurrent breast cancer treated with chemotherapy.American Journal of Clinical Oncology.  21:501-504. 1998
    1998 Current treatment options for malignant melanoma.Drugs.  55:791-799. 1998
    1998 Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.Lancet.  351:1451-1467. 1998
    1998 Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.Journal of Clinical Oncology.  16:1743-1751. 1998
    1998 Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin.Oncology.  55:116-121. 1998
    1998 Hepatocellular carcinoma.Cancer Treatment and Research.  98:83-109. 1998
    1998 Prognostic factors in metastatic malignant melanoma. An analysis of 236 patients treated on clinical research studies at the Department of Medical Oncology, University of Pretoria, South Africa from 1972-1992.Oncology.  55:59-64. 1998
    1996 Granulocyte-colony stimulating factor fails to prevent leucopenia caused by CEMP in elderly patients with aggressive lymphoma.South African Medical Journal.  86:1564. 1996
    1996 Granulocyte-macrophage-colony-stimulating factor support in patients with acute non-lymphatic leukemia.Oncology.  53:482-487. 1996
    1996 A randomised study of CGS 16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer.Annals of Oncology.  7:465-469. 1996
    1996 Cisplatin versus cisplatin plus D-Trp-6-LHRH in the treatment of ovarian cancer: a pilot trial to investigate the effect of the addition of a GnRH analogue to cisplatin.Oncology.  53:313-317. 1996
    1996 Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma.American Journal of Clinical Oncology.  19:268-270. 1996
    1996 A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia.South African Medical Journal.  86:549-550. 1996
    1995 Treatment of metastatic malignant melanoma.Anti-Cancer Drugs.  6:709-716. 1995
    1995 Antiemetic efficacy of tropisetron in patients failing previous antiemetic therapy.Oncology.  52:427-431. 1995
    1995 Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.Medical Oncology.  12:35-40. 1995
    1994 Recombinant human erythropoietin in the treatment of cancer-related anaemia.Oncology.  51:497-501. 1994
    1994 FIVB plus GM-CSF in metastatic colorectal cancer.Investigational New Drugs.  12:49-52. 1994
    1994 Phase II trial of fotemustine in patients with metastatic malignant melanoma.Investigational New Drugs.  12:251-254. 1994
    1994 Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: an Eastern Cooperative Oncology Group study.Journal of Clinical Oncology.  12:45-49. 1994
    1993 Combined modality treatment of gastrointestinal cancer.Current Opinion in Oncology.  5:710-718. 1993
    1993 Postmenopausal breast cancer. Drug therapy in the 1990s.Drugs and Aging.  3:106-121. 1993
    1993 A randomized trial of mitomycin-C (M) versus mitomycin-C plus high-dose medroxyprogesterone acetate (MMPA) in the treatment of patients with advanced breast cancer.American Journal of Clinical Oncology.  16:14-17. 1993
    1993 New formulation intravenous melphalan in the treatment of patients with metastatic renal cancer.Investigational New Drugs.  11:93. 1993
    1992 Cyclophosphamide, doxorubicin and fluorouracil (CAF) plus depo-buserelin in the treatment of premenopausal women with metastatic breast cancer.Annals of Oncology.  3:849-853. 1992
    1992 An extended phase II trial of ifosfamide plus mesna in malignant mesothelioma.Investigational New Drugs.  10:337-343. 1992
    1992 Metastatic breast cancer: higher versus low dose maintenance treatment when only a partial response or a no change status is obtained following doxorubicin induction treatment. An Eastern Cooperative Oncology Group study.Annals of Oncology.  3:768-770. 1992
    1992 Current approaches in the management of patients with hepatocellular carcinoma.Anticancer Drug Design.  4:87-89. 1992
    1992 Mitomycin C + high-dose medroxyprogesterone versus cyclophosphamide+doxorubicin plus fluorouracil as first-line treatment for metastatic breast cancer.Oncology.  49:418-421. 1992
    1991 Factors predicting for response, time to treatment failure, and survival in women with metastatic breast cancer treated with DAVTH: a prospective Eastern Cooperative Oncology Group study.Journal of Clinical Oncology.  9:2153-2161. 1991
    1991 Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.Journal of Clinical Oncology.  9:1403-1408. 1991
    1991 Adjuvant therapy now indicated for colorectal carcinoma.South African Medical Journal.  79:692. 1991
    1991 Long term follow-up of patients with advanced prostatic cancer treated with nasal buserelin.Annals of Oncology.  2:303-304. 1991
    1991 Effect of chemotherapy with or without buserelin on serum hormone levels in premenopausal women with breast cancer.European Journal of Cancer.  27:1208-1211. 1991
    1991 Sister chromatid exchanges in lymphocyte cultures of patients previously treated with dibromodulcitol.Oncology.  48:253-257. 1991
    1990 High versus low dose granisetron, a selective 5HT3 antagonist, for the prevention of chemotherapy-induced nausea and vomiting.Investigational New Drugs.  8:407-409. 1990
    1990 Survival of premenopausal women with metastatic breast cancer. Long-term follow-up of Eastern Cooperative Group and Cancer and Leukemia Group B studies.Cancer.  66:1621-1629. 1990
    1989 Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.Investigational New Drugs.  7:261-267. 1989
    1988 High-dose medroxyprogesterone acetate plus mitomycin-C or vindesine in the treatment of advanced breast cancer.American Journal of Clinical Oncology.  11:431-434. 1988
    1988 Cyclophosphamide, mitoxantrone, vincristine and prednisone in the treatment of non-Hodgkin's lymphoma.Oncology.  45:378-379. 1988
    1985 Mesothelioma or ovarian carcinoma? A case report.South African Medical Journal.  68:676-677. 1985

    Book

    Year Title Altmetric
    2006 Breast cancer in women of African descent 2006

    Chapter

    Year Title Altmetric
    2006 Adjuvant therapy of breast cancer.  153-219. 2006

    Research Overview

  • Carla I. Falkson has been actively involved in development and planning of trials, with an emphasis on clinical trials. Her research has been focused on developing innovative treatments for patients with cancer, as well as coordinating other aspects of cancer research. Her major interests are in the areas of breast cancer and melanoma. She is actively involved in planning ECOG's scientific research program. Examples of research include: Breast Cancer – designing adjuvant and metastatic trials, with emphasis on translational research and quality of life issues for women with breast cancer. Dr. Falkson is actively involved with development and planning of trials, with an emphasis on clinical trials in breast cancer. She is interested in fostering collaboration between groups and is Principal Investigator for UAB's Eastern Cooperative Oncology Group(ECOG) projects. She has been an active member of the ECOG Breast Committee since 1989 and a member of various other international breast cancer groups (for example BCIRG/CIRC). Examples of research include the use of bisphosphonates in breast cancer and chairing studies with these agents such as NSABP-B 34 and S 0307 for ECOG. The use of antiangiogenic agents in breast cancer and treatments for Her2-positive breast cancer are also areas of focus. Dr. Falkson has been actively involved with quality assurance in cancer research, including chairing UAB's Quality Assurance Committee and ECOG's Audit committee, and has been a member of the ECOG Publications Committee and Audit Committee since 1996. Other examples of research interests include: Bone metastatases in breast cancer; bisphosphonates as adjuvant therapy for breast cancer; clinical aspects of gamma delta T-cells in breast cancer; circulating serum-Her-2 neu in serum in breast cancer; Herceptin in breast cancer and tumor exosomal jak3BP-mediated immunosuppresion of NK cells in patients with breast cancer. Dr Falkson has also been involved with genetic studies (BRCA determination) in various South African populations. (Done in collaboration with the Department of Human Genetics, University of Pretoria) and co-chaired various breast cancer genetic studies in Pretoria (1995-2001) and co-chairman of various genetic studies eg BRCA1 & 2 determinations (see publications) and been a member of the ECOG Gene Therapy Committee (1997-2001).
  • Principal Investigator On

  • Private Grant  awarded by Pfizer Pharmaceuticals 2017 - 2025
  • Private Grant  awarded by ELI LILLY AND COMPANY 2018 - 2023
  • TBCRC 035 UAB 15114: Palbociclib in Combination with Fulvestrant or Tamoxifen as Treatment for Hormone Receptor Positive Metastatic Breast Cancer with Prior Chemotherapy for Advanced Disease: A Phase II Study with Pharmacodynamics Markers (TBCRC 35)  awarded by Johns Hopkins University 2016 - 2021
  • Private Grant  awarded by EMD SERONO 2016 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2021
  • UAB 1428: A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer  awarded by HOOSIER CANCER RESEARCH NETWORK 2015 - 2020
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2012 - 2020
  • Private Grant  awarded by INNOCRIN PHARMACEUTICALS, INC. 2016 - 2020
  • Private Grant  awarded by MEDIVATION, INC 2018 - 2020
  • TBCRC030 - A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker  awarded by Johns Hopkins University 2014 - 2019
  • Private Grant  awarded by ASTELLAS PHARMA US, INC. 2017 - 2019
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2014 - 2019
  • UAB 1527 – A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer  awarded by Johns Hopkins University 2017 - 2019
  • ECOG-ACRIN Purchase Service Agreement  awarded by Eastern Cooperative Oncology Group 2014 - 2019
  • Private Grant  awarded by MEDIVATION, INC 2017 - 2018
  • Private Grant  awarded by ALPHA ONCOLOGY, INC 2013 - 2016
  • UAB 110/TBCRC 012: ABCDE: A Phase II Randomized Study of Adjuvant Bevacizumab, Metronomic Chemotherapy (CM), Diet and Exercise after Preoperative Chemotherapy for Breast Cancer.  awarded by Dana-Farber Cancer Institute 2011 - 2016
  • UAB Eastern Cooperative Oncology Group Operations Office  awarded by Eastern Cooperative Oncology Group 2010 - 2016
  • CALGB Tissue Banking  awarded by University of Chicago 2010 - 2015
  • Multicenter Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC--T) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (AC--TH) and with Docetaxel, Platinum Salt and Trastuzumab (TCH) in the Treatment of Node Positive and High Risk Node Negative Adjuvant Patients with Operable Breast Cancer Containing the HER2NEU Alteration  awarded by BREAST CANCER INTERNATIONAL RESEARCH GROUP 2001 - 2014
  • Purchase Services Agreement - ECOG  awarded by FRONTIER SCIENCE & TECHNOLOGY RESEARCH FOUNDATION, INC. 2001 - 2014
  • A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab  awarded by BREAST CANCER INTERNATIONAL RESEARCH GROUP 2008 - 2014
  • Private Grant  awarded by Bayer HealthCare 2007 - 2014
  • Private Grant  awarded by GlaxoSmithKline 2008 - 2014
  • A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination with Doxorubicin and Cyclophosphamide (TAC) Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel (AC--T) as Adjuvant Treatment of Operable Breast Cancer HER2Neu Negative Patients with Positive Axillary Lymph Nodes  awarded by BREAST CANCER INTERNATIONAL RESEARCH GROUP 2011 - 2013
  • Private Grant  awarded by Genentech 2005 - 2013
  • Investigator On

  • Private Grant  awarded by GlaxoSmithKline 2017 - 2025
  • UAB17127:A phase Ib trial of fulvestrant, palbociclib (CDK4/6 inhibitor) and erdafitinib (JNJ- 42756493, pan-FGFR tyrosine kinase inhibitor) in ER+/HER2–/FGFR-amplified metastatic breast cancer (MBC)  awarded by VANDERBILT UNIVERSITY 2018 - 2023
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2018 - 2023
  • Private Grant  awarded by Genentech 2018 - 2023
  • Private Grant  awarded by ZYMEWORKS BIOPHARMACEUTICALS 2018 - 2023
  • XUAB 17109-TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progression  awarded by Johns Hopkins University 2018 - 2023
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2022
  • Private Grant  awarded by CALITHERA BIOSCIENCES INC 2017 - 2022
  • Plasma Tumor DNA and Pathologic Complete Response in Early-Stage, High-Risk Breast Cancer  awarded by Johns Hopkins University 2017 - 2022
  • Private Grant  awarded by CLOVIS ONCOLOGY 2017 - 2022
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2016 - 2022
  • Private Grant  awarded by TESARO, INC. 2016 - 2021
  • Private Grant  awarded by REXAHN PHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by Genentech 2016 - 2021
  • Private Grant  awarded by INNOCRIN PHARMACEUTICALS, INC. 2016 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2017 - 2021
  • Private Grant  awarded by CASCADIAN THERAPEUTICS 2016 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2021
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2016 - 2021
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2016 - 2021
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2017 - 2021
  • UAB 1643- A Randomized Phase II Trial of Fulvestrant With or Without Ribociclib After Progression on Aromatase Inhibition Plus Cyclin-Dependent Kinase 4/6 Inhibition in Patients with Unresectable or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer  awarded by Columbia University 2016 - 2020
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2015 - 2020
  • TBCRC 038: Diversity in the Tumor Genome and Microenvironment as Drivers of DCIS Progession  awarded by Duke University 2018 - 2020
  • Southwest Oncology Group Purchase Service Agreement  awarded by Oregon Health & Science University 2015 - 2020
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2015 - 2019
  • UAB 1764:The Targeted Agent and Profiling Utilization Registry (TAPUR) Study  awarded by American Society of Clinical Oncology 2017 - 2019
  • CITY Health II - The Center for the Study of Community Health  awarded by National Center for Chronic Disease Prevention & Health Promo./CDC/DHHS 2014 - 2019
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2019
  • UAB 1326: A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-Amplified but HER2 Mutant Breast Cancer  awarded by Washington University 2013 - 2019
  • UAB 1761: A Randomized, Placebo-Controlled, Double-Blind, Phase II trial of Nanoparticle Albumin-Bound Paclilaxel (Nab-Paclilaxel, Abraxane®) with or without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple Negative Breast Cancer.  awarded by University of Chicago 2017 - 2019
  • TBCRC 026/UAB 1367: A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer (ML28190)  awarded by Johns Hopkins University 2014 - 2019
  • Utilizing Multiomic Advanced Diagnostics to Identify Palbociclib Response Predictors and a Post-treatment Multiomic Signature for Patients with ER+/HER2- Metastatic Breast Cancer  awarded by THE SIDE-OUT FOUNDATION 2017 - 2019
  • UAB 1174: Investigation of Serial Studies to Predict your Therapeutic Response with Imaging and Molecular Analysis 2  awarded by QUANTUM LEAP HEALTH CARE 2012 - 2019
  • Private Grant  awarded by CELLDEX THERAPEUTICS, INC. 2014 - 2019
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2013 - 2019
  • TBCRC 036 (UAB 1366): Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab + Pertuzumab, or Combination Trastuzumab + Lapatinib  awarded by Lineberger Comprehensive Care Center 2014 - 2019
  • TBCRC 033 UAB 1568: A Randomized Phase II study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage 1 HER2-Positive Breast Cancer (ATEMPT Trial)  awarded by Dana-Farber Cancer Institute 2015 - 2018
  • Private Grant  awarded by JANSSEN RESEARCH & DEVELOPMENT, LLC 2013 - 2018
  • Private Grant  awarded by PHARMACYCLICS, INC. 2015 - 2018
  • Private Grant  awarded by SEATTLE GENETICS, INC. 2013 - 2018
  • TBCRC 037 UAB 1644:A Trial of Endocrine Response In Women with Invasive Lobular Breast Cancer.  awarded by University of Pittsburgh 2016 - 2018
  • Alliance for Clinical Trials in Oncology Payment Agreement  awarded by MAYO CLINIC 2017 - 2018
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2016 - 2018
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2015 - 2017
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2014 - 2017
  • Private Grant  awarded by Novartis Pharma AG 2014 - 2017
  • A Phase II Study Evaluating the Efficacy and Tolerability of Everolimus (RAD001) in Combination with Trastuzumab and Vinorelbine in the Treatment of Progressive HER2-Positive Breast Cancer Brain Metastases  awarded by University of North Carolina at Chapel Hill 2012 - 2017
  • Private Grant  awarded by REXAHN PHARMACEUTICALS, INC. 2016 - 2017
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2012 - 2017
  • Private Grant  awarded by OBI PHARMA, INC. 2012 - 2017
  • Private Grant  awarded by Sanofi US Services Inc 2012 - 2017
  • Comprehensive Cancer Center Core Support Grant  awarded by National Cancer Institute/NIH/DHHS 2016 - 2017
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2014 - 2016
  • Private Grant  awarded by ONCOTHYREON, INC. 2015 - 2016
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY 2011 - 2016
  • Private Grant  awarded by INCYTE CORPORATION 2013 - 2016
  • NCTN Deep South Research Consortium  awarded by National Cancer Institute/NIH/DHHS 2014 - 2016
  • UAB 1019/TBCRC 015: Investigation of Genetic Determinants of Capecitabine Toxicity  awarded by Johns Hopkins University 2010 - 2015
  • A Prospective Analysis of Surgery in Patients Presenting with Stage IV Breast Cancer - TBCRC 013 / UAB 0953  awarded by Johns Hopkins University 2009 - 2015
  • UAB 1018/TBCRC 011; Bicalutamide for the Treatment of Androgen Receptor Positive (AR(+), Estrogen Receptor Negative, Progesterone Receptor Negative (ER(-)/PR(-), Metastatic Breast Cancer Patients: A Phase II Feasibility Study  awarded by Johns Hopkins University 2009 - 2015
  • Private Grant  awarded by Pfizer Inc., U.S. Pharmaceuticals Group 2015
  • Private Grant  awarded by ABBVIE INC 2014 - 2015
  • Private Grant  awarded by Genentech 2011 - 2015
  • UAB 1033/TBCRC 018: A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201) in Combination with Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis  awarded by Johns Hopkins University 2010 - 2015
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION 2011 - 2015
  • Private Grant  awarded by TRACON PHARMACEUTICALS, INC. 2012 - 2015
  • Private Grant  awarded by SYNTA PHARMACEUTICALS 2013 - 2014
  • Targeting Signal Transduction Pathways for the Treatment and Prevention of Breast Cancer  awarded by UNIVERSITY OF TEXAS (M.D. ANDERSON CANCER CENTER) 2012 - 2014
  • Private Grant  awarded by Genentech 2007 - 2014
  • Private Grant  awarded by MERRIMACK PHARMACEUTICALS, INC. 2013 - 2014
  • Private Grant  awarded by AVEO PHARMACEUTICALS, INC 2013 - 2014
  • Private Grant  awarded by MERRIMACK PHARMACEUTICALS, INC. 2012 - 2014
  • UAB 1052-TBCR020: The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Lobular Neoplasia of the Breast by Core Needle Biopsy  awarded by Johns Hopkins University 2011 - 2013
  • Private Grant  awarded by INCYTE CORPORATION 2013
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2012 - 2013
  • Neoadjuvant Trial of Lapatinib for the Treatment of Women With DCIS Breast Cancer  awarded by UNIVERSITY OF TEXAS (M.D. ANDERSON CANCER CENTER) 2011 - 2012
  • Education And Training

  • Doctor of Medicine, University of Pretoria
  • Full Name

  • Carla Falkson
  • Blazerid

  • cfalkson